Investigational drugs for retinal vein occlusion

Published on May 9, 2016in Expert Opinion on Investigational Drugs5.081
· DOI :10.1080/13543784.2016.1181750
Dominique Bremond-Gignac1
Estimated H-index: 1
ABSTRACTIntroduction: Retinal vein occlusion (RVO) is the second most common retinal vascular disorder. This multifactorial disease frequently leads to visual impairment. Some risk factors for RVO can be managed prophylactically. Given the complex physiopathology of RVO, most of the latest therapeutic strategies focus on secondary clinical features (such as macular oedema and neovascularization).Areas covered: This author reviews ongoing, prospective, open-label Phase I and Phase II clinical trials of novels treatments for RVO (primarily intravitreal steroids and anti-VEGF agents). Specifically, they review the pharmacokinetics, safety profile, study design and adverse events associated with innovative drugs in clinical development.Expert opinion: A number of innovative, early-phase clinical trials are based on combination therapy with an anti-VEGF agent and steroids. There is good evidence that early treatment of RVO has clinical benefits. Larger, randomized studies are now required for a better understa...
📖 Papers frequently viewed together
9 Citations
9 Citations
1 Author (Shwu-Jiuan Sheu)
#1Jay Chhablani (LVPEI: L V Prasad Eye Institute)H-Index: 28
#2Raja NarayananH-Index: 21
Last. Michael W. StewartH-Index: 29
view all 5 authors...
To evaluate the safety of intravitreal ziv-aflibercept (Zaltrap) in the treatment choroidal neovascularization secondary to age-related macular degeneration.Eligible eyes with choroidal neovascularization secondary to age-related macular degeneration each received a single intravitreal injection of ziv-aflibercept. Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injection, and International Society for Clinical Electr...
31 CitationsSource
#1Jose S. Pulido (Mayo Clinic)H-Index: 64
#2Christina J. Flaxel (OHSU: Oregon Health & Science University)H-Index: 29
Last. Timothy W. Olsen (Emory University)H-Index: 40
view all 6 authors...
Retinal Vein Occlusions Preferred Practice Pattern® Guidelines New evidence-based Retinal Vein Occlusions Preferred Practice Pattern® (PPP) guidelines, discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.
29 CitationsSource
#1Florence Coscas (University of Paris)H-Index: 23
#2Agnès Glacet-Bernard (University of Paris)H-Index: 23
Last. Eric H. Souied (University of Paris)H-Index: 32
view all 8 authors...
Purpose To evaluate the optical coherence tomography angiography (OCT angiography) appearance of the superficial and deep capillary plexa in eyes with retinal vein occlusion (RVO) and to compare these findings with those of fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD OCT). Design Retrospective observational case series. Methods Patients presenting with RVO to Creteil University Eye Clinic were retrospectively evaluated. All patients had undergone a comprehen...
190 CitationsSource
#1Thanh T. Nguyen (University of Melbourne)H-Index: 22
#2Robyn H. Guymer (University of Melbourne)H-Index: 71
Age-related macular degeneration (AMD) is a progressive, degenerative disease of the retina that occurs with increasing incidence with age and ranks third among the global causes of visual impairment. VEGF has been implicated in the development and progression of neovascular AMD. Drugs that block VEGF, leading to regression of the abnormal blood vessels, are the mainstay of treatment of neovascular AMD, particularly for subfoveal neovascular lesions. Anti-VEGF agents currently in use in neovascu...
23 CitationsSource
#1Elisa Dominguez (University of Paris)H-Index: 9
#2William Raoul (François Rabelais University)H-Index: 20
Last. Florian Sennlaub (University of Paris)H-Index: 42
view all 7 authors...
Aims Branch retinal vein occlusion (BRVO) leads to extensive vascular remodeling and is important cause of visual impairment. Although the vascular morphological changes following experimental vein occlusion have been described in a variety of models using angiography, the underlying cellular events are ill defined. Methods and Results We here show that laser-induced experimental BRVO in mice leads to a wave of TUNELpositive endothelial cell (EC) apoptosis in the upstream vascular network associ...
25 CitationsSource
#1Mei Chen (WMU: Wenzhou Medical College)H-Index: 1
#2X. Li (WMU: Wenzhou Medical College)H-Index: 3
Last. Lingyun Cheng (UCSD: University of California, San Diego)H-Index: 36
view all 5 authors...
Abstract Suprachoroidal injection is an emerging technique for drug delivery to the posterior segment, which is hard to reach by non-invasive approaches. However, the injection technique varies and the associated ocular safety is not well understood. In addition, it is not clear if drug formulation is a major factor in optimizing pharmacodynamics using this technique. The current study was designed to compare the suprachoroidal injection of different drug formulations and to characterize the saf...
49 CitationsSource
#1Peter A. Campochiaro (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 121
#2Raafay Sophie (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 19
Last. Kevin G. PetersH-Index: 52
view all 11 authors...
Purpose AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and reduces vascular leakage and neovascularization in mouse models. The purpose of this study was to test the safety, tolerability, pharmacokinetics, and biological activity of AKB-9778 in patients with diabetic macular edema (DME). Design Open-label, dose-escalation clinical trial. Participants Four dose cohorts of 6 patients with DME self-admin...
55 CitationsSource
#5David M. Brown (Houston Methodist Hospital)H-Index: 42
#6Robert Vitti (Regeneron)H-Index: 23
Last. Julia A. Haller (Wills Eye Institute)H-Index: 60
view all 13 authors...
Purpose To determine week 52 efficacy and safety outcomes in eyes with macular edema after branch retinal vein occlusion (BRVO) treated with 2 mg intravitreal aflibercept injection (IAI) compared with grid laser. Design VIBRANT was a double-masked, randomized, phase 3 trial. Participants Eyes randomized and treated in VIBRANT were followed to week 52. Methods In the IAI group, eyes received IAI every 4 weeks through week 24 and IAI every 8 weeks through week 48 with rescue grid laser if needed a...
222 CitationsSource
#1Valentina Sarao (University of Udine)H-Index: 14
#2Federica Bertoli (University of Udine)H-Index: 3
Last. Paolo Lanzetta (University of Udine)H-Index: 32
view all 4 authors...
Introduction: Retinal vein occlusion (RVO) is a common vascular condition, which may cause blindness and impaired vision as a result of the development of macular oedema. The management of macular oedema due to RVO is complex and a multidisciplinary approach is required in order to limit disease progression and achieve a better clinical outcome.Areas covered: An update and a brief review on the current treatment strategies were provided in patients with macular oedema following RVOs. Evidence av...
9 CitationsSource
#1Jeffrey S. HeierH-Index: 57
#2W. Lloyd ClarkH-Index: 16
Last. Julia A. Haller (Wills Eye Institute)H-Index: 60
view all 12 authors...
Purpose To evaluate the efficacy and safety of intravitreal aflibercept injection (IAI) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). Design Randomized, double-masked, phase 3 trial. Participants A total of 188 patients with macular edema secondary to CRVO. Methods Patients received IAI 2 mg (IAI 2Q4) (n = 114) or sham injections (n = 74) every 4 weeks up to week 24. During weeks 24 to 52, patients from both arms were evaluated monthly and received IAI as...
179 CitationsSource
Cited By1
#1Rajkumar PatilH-Index: 2
#2Chee Wai Wong (Singapore National Eye Center)H-Index: 19
Last. Tien Yin Wong (Visual Sciences)H-Index: 178
view all 8 authors...
Age-related macular degeneration (AMD), diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV) and retinal vein occlusion (RVO) taken together are leading cause of blindness worldwide. Neovascularization in these retinal disorders is induced largely by vascular endothelial growth factor A (VEGF-A) and progresses rapidly to blindness if left untreated. VEGF-A, with a central role in both normal and pathologic vascular growth within the eye, binds to VEGF-A receptors (e.g., Flt-1) o...
2 CitationsSource